Gary W Middleton
University of Birmingham · St. Luke's Cancer Centre at Royal Surrey County Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gary W Middleton as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:04 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02664935 · National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerUniversity of Birmingham · completed · Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma · principal investigator
- Ph3NCT00425360 · Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerRoyal Liverpool University Hospital · completed · Pancreatic Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:04 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- 1,553 citationsRCR 58.0
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.Lancet Oncol · 2014482 citationsRCR 15.0
- 235 citationsRCR 9.3
- Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.Ann Oncol · 199874 citationsRCR 2.6
- Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.Ann Oncol · 201353 citationsRCR 1.5
- Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.J Clin Oncol · 202537 citationsRCR 9.4
- Diagnostic accuracy of 99Tcm-HIDA with cholecystokinin and gallbladder ejection fraction in acalculous gallbladder disease.Nucl Med Commun · 200128 citationsRCR 1.0
- Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue.Bone Marrow Transplant · 199613 citationsRCR 0.5